Evaxion Biotech has priced a public offering, seeking to raise $10.8 million before expenses, with closing anticipated tomorrow.

New US President Donald Trump and his administration have confirmed that lowering the cost of prescription drugs for Americans is a top priority, suggesting that they will continue the work of the ...

Cullinan Therapeutics and its partner Taiho Pharmaceutical have reported a win for zipalertinib, with the primary endpoint of a Phase IIb trial being met. The data, which include a positive safety ...

US pharma giant Merck & Co today revealed an early stop to the Phase III HYPERION study evaluating Winrevair (sotatercept-csrk) versus placebo (both in combination with background therapy) in recently ...

Danish CNS specialist Lundbeck announced positive results from the 12-month open-label extension of the Phase Ib/IIa PACIFIC trial, evaluating bexicaserin in participants aged 12-65 with developmental ...

The presentation of Japanese drugmaker Takeda’s latest financial results were presented Thursday, though they took a back ...

Swiss pharma giant Roche today released full-year 2024 financials, showing that group sales grew 7% at constant exchange ...

UK health technology assessor the National Institute for Health and Care Excellence (NICE) has recommended Acarizax (12 ...

In a long-term succession plan, the board of directors at Japan’s largest drugmaker Takeda has made the decision unanimously ...

French pharma major Sanofi (Euronext: SAN) has met analyst estimates for its fourth-quarter 2024 profit and confirmed plans for a 5 billion euro ($5.5 billion) share buyback program in 2025. The ...

A clinical-stage biopharma company developing therapeutic product candidates for metabolic diseases, such as obesity, by ...

The global neuromuscular disease therapeutics market is projected to grow by $13.73 billion between 2025 and 2029, according ...